More on OCS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/3/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Oculis Holding (NQ:OCS)
Delayed: 7.96 +0.06 (0.76%)
Prev. Close $7.90  
Open$7.88 
52 Wk High$8.14 
52 Wk Low$6.68 
Day High$8.03 
Day Low$7.65 
P/E 265.33  
EPS$0.03 
Volume206,969 


Oct 23, 2026 07:37 AM H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)
Oct 22, 2026 02:00 AM Oculis reports biomarker data from Phase 2 trial of Privosegtor
Oct 22, 2026 02:00 AM Oculis reports Phase 2 biomarker data for optic neuritis drug
Oct 22, 2026 02:00 AM Oculis Reports New Phase 2 ACUITY Biomarker Data  Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
Oct 22, 2026 02:00 AM Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
Oct 21, 2026 06:50 AM H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)
Oct 20, 2026 02:00 AM Oculis to present Privosegtor biomarker data at MS conference
Oct 20, 2026 02:00 AM Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Oct 19, 2026 06:03 AM Oculis completes enrollment in PREDICT-1 dry eye disease trial
Oct 19, 2026 06:02 AM Oculis completes enrollment in dry eye disease trial PREDICT-1
View All Articles

Entities mentioned with OCS

View All Entities